Percheron Therapeutics AI Stock Analysis
Want to see AU:PER full AI Analyst Report?
Percheron Therapeutics (PER) AI Stock Analysis
Percheron Therapeutics
(ASX:PER)
The score is driven primarily by weak financial performance: Percheron generates no revenue, has lost money every year, and depends entirely on external financing. A materially reduced net loss and a roughly two-thirds cut in cash burn in the latest year are genuine positives, as is the virtually debt-free balance sheet, but a shrinking asset and equity base with roughly $5M of annual burn points to limited runway and probable dilution. Valuation offers no support — earnings are negative and there is no dividend — and the absence of trend and momentum indicators leaves no technical confirmation for this sub-cent, highly speculative stock. This remains a binary, pipeline-dependent story rather than an investment supported by current fundamentals.
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 4.76M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- -0.02
- Revenue Growth
- ―
- EPS Growth
- 72.60%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Percheron Therapeutics Business Overview & Revenue Model
Company Description
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limite...
How the Company Makes Money
Percheron Therapeutics does not appear to have a recurring commercial product revenue stream; as a clinical-stage biotech, it typically would not generate meaningful sales until regulatory approval and commercialization of a drug. As a result, the co...
Percheron Therapeutics Financial Statement Overview
Summary
Percheron is a pre-revenue clinical-stage developer with zero revenue across six fiscal years and persistent losses (Income Statement score 17). The one clear positive is a sharp improvement in the latest year: net loss narrowed from about $14.9M to $4.8M and cash burn fell roughly 68% to about $5.0M (Cash Flow score 22), reflecting aggressive cost containment after a pipeline setback. The balance sheet is the strongest element (score 51) — essentially debt-free with equity funding about 92% of assets — but the capital base has eroded from roughly $22.4M in total assets in FY2022 to about $8.2M today. With ongoing annual burn near $5M, runway is limited and a dilutive capital raise appears likely.
Income Statement
17Very NegativeBalance Sheet
51NeutralCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -219.56K | -219.56K | -67.98K | -79.42K | -95.20K | -89.22K |
| EBITDA | -5.40M | -5.40M | -16.27M | -11.84M | -13.25M | -7.52M |
| Net Income | -4.79M | -4.79M | -14.92M | -11.92M | -11.38M | -5.81M |
Balance Sheet | ||||||
| Total Assets | 8.22M | 8.22M | 12.44M | 14.53M | 12.84M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 4.05M | 4.05M | 10.17M | 11.87M | 10.97M | 19.23M |
| Total Debt | 27.79K | 27.79K | 25.86K | 39.87K | 142.10K | 227.40K |
| Total Liabilities | 692.18K | 692.18K | 2.43M | 5.17M | 2.87M | 1.30M |
| Stockholders Equity | 7.53M | 7.53M | 10.00M | 9.36M | 9.98M | 21.14M |
Cash Flow | ||||||
| Free Cash Flow | -4.97M | -4.97M | -15.65M | -10.12M | -8.18M | -7.81M |
| Operating Cash Flow | -4.96M | -4.96M | -15.64M | -10.12M | -8.15M | -7.81M |
| Investing Cash Flow | -3.09M | -3.09M | -7,240 | -3,606 | -29.29K | -3,913 |
| Financing Cash Flow | 1.93M | 1.93M | 13.95M | 11.02M | -85.30K | 21.02M |
Percheron Therapeutics Peers Comparison
Overall Rating
AU:CAN53Neutral
AU:LGP51.5Neutral
AU:IDT43Neutral
AU:VIT41Neutral
AU:PKP39Underperform
AU:PER33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
| 52Neutral | AUD 54.65M | -14.35 | -1.67% | ― | 15.21% | -141.82% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | AUD 19.03M | -7.19 | -13.81% | ― | 5.93% | 66.32% | |
| 41Neutral | AUD 11.27M | -2.54 | -9.80% | ― | 5.74% | -222.22% | |
| 39Underperform | AUD 17.41M | -5.07 | 4388.00% | ― | -19.73% | 50.34% | |
| 33Underperform | AUD 6.94M | -0.85 | -65.33% | ― | ― | 72.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:PER | Percheron Therapeutics Limited | ― | ― | ― | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:LGP | Little Green Pharma Ltd. | 0.07 | -0.07 | -52.86% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.01 | -35.00% | |
| AU:IDT | IDT Australia Limited | 0.05 | -0.01 | -22.03% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.05 | -73.44% |
Percheron Therapeutics Corporate Events
Percheron Updates Top 20 Option Holders List
Percheron Therapeutics, a biotechnology company focused on novel oncology therapies, released an updated list of its 20 largest holders of listed options expiring 15 April 2028 at an exercise price of $0.01. The update corrects registry records for t...
Percheron Director Acquires 10 Million Quoted Options
Percheron Therapeutics Limited is a therapeutics company, although the notice provides no further details about its products or market focus.Director Michael Baker acquired an indirect interest in 10 million quoted options through related entity DMMY...
Percheron Releases Top 20 PERAQ Option Holders
Percheron Therapeutics provided the top 20 holders and distribution list for its newly issued and quoted PERAQ options, which expire on 15 April 2028 and carry a $0.01 exercise price. The top 20 holders control 350.8 million options, representing 61%...
Percheron Seeks Quotation of 574.99 Million Options
Percheron Therapeutics operates in the therapeutics industry, but the release does not identify its products, services, or specific market focus.The company has applied to quote 574,987,505 options issued on November 6, 2026, with a one-cent exercise...
Percheron Updates Options Issue and Seeks ASX Quotation
Percheron Therapeutics has lodged a prospectus dated 4 November 2026 for an offer of options previously announced on 1 September 2026. The company is seeking ASX quotation of the options and amending their issue date, updating the proposed securities...
Percheron Seeks ASX Quotation for Options Following Prospectus
Percheron Therapeutics Limited operates in the biotechnology and therapeutics industry, although the release does not provide details about its products or specific market focus.The company lodged a prospectus dated 4 November 2026 for an offer of op...
Percheron Therapeutics Announces Offers For Up To 280 Million New Options
Percheron Therapeutics has issued a prospectus for offers of up to 280 million new options, comprising 230 million options for placement participants and 50 million for joint lead managers or their nominees. The document outlines quotation conditions...
FDA Clears Vanderbilt Trial of Percheron’s HMBD-002 in AML
Percheron Therapeutics is an international biotechnology company developing novel oncology therapies, including HMBD-002, an investigational VISTA-targeting treatment, with a focus on hematologic malignancies. The U.S. FDA has cleared a Vanderbilt He...
Percheron Therapeutics Wins ASX Waiver to Quote PERAQ Options After Capital Raising
Percheron Therapeutics has secured a waiver from ASX Listing Rule 6.23.4, allowing quotation of a large pool of existing PERAQ options that were previously unquoted, including entitlement, adviser and joint lead manager options. The move follows a re...
Percheron bolsters cancer pipeline with new trial, Invion tie-up and fresh leadership
Percheron Therapeutics reported a busy September quarter, securing a clinical research agreement with Vanderbilt Health for an investigator-sponsored, multi-centre trial of its lead antibody HMBD-002 in combination with standard care for high-risk ac...
Invion and Percheron Launch Preclinical Cancer Combo Study with Photosoft and VISTA Antibody
Invion Limited and Percheron Therapeutics have entered a non-exclusive preclinical research collaboration to test Percheron’s anti-VISTA monoclonal antibody HMBD-002 with Invion’s Photosoft INV043 next-generation photodynamic therapy in solid tumour...
Percheron and Invion Launch Preclinical Cancer Combo Study
Percheron Therapeutics has entered a preclinical research collaboration with Invion to evaluate HMBD-002, its clinical-stage anti-VISTA immune checkpoint inhibitor, in combination with Invion’s Photosoft next-generation photodynamic therapy platform....
Percheron Therapeutics seeks ASX quotation for major new share issue
Percheron Therapeutics has applied to the ASX for quotation of 138,000,000 new fully paid ordinary shares, issued at $0.005 per share. The shares, to be quoted from October 15, 2026, follow a previously lodged capital raising notice, signalling a sig...
Percheron Grants 75 Million Performance Units to Director Michael Baker
Percheron Therapeutics has disclosed a change in director Michael Baker’s interests following the issuance of 75,000,000 Performance Restricted Stock Units. The indirect interest arises via his role as a director of related entity DMMY Holdings Pty L...
Percheron Therapeutics Issues 75 Million Unquoted Performance Stock Units
Percheron Therapeutics has issued 75 million unquoted Performance Restricted Stock Units as part of a previously flagged equity transaction. The new securities, which will not be quoted on the ASX, reflect the company’s continued use of performance-l...
Percheron Therapeutics Wins Strong Shareholder Backing at 2026 AGM
Percheron Therapeutics Limited has reported the outcomes of its 2026 Annual General Meeting, where all resolutions were decided by poll and received strong shareholder support. The Board expressed appreciation to investors for their engagement, signa...
Percheron advances HMBD-002 program as transition year reshapes pipeline
Percheron Therapeutics used its 2026 Annual General Meeting in Melbourne, held both in person and virtually, to highlight a year of significant transition centred on its newly in-licensed oncology asset HMBD-002. The company reported it has manufactu...
Percheron Therapeutics Plans Issue of 75 Million Performance Restricted Stock Units
Percheron Therapeutics has notified the ASX of a proposed issue of up to 75 million Performance Restricted Stock Units, to be treated as a new class of securities and targeted for issue on October 8, 2026. The placement underscores the company’s use...
Percheron Therapeutics Names New CEO to Drive Oncology Strategy and Investor Outreach
Percheron Therapeutics has appointed experienced biotech executive Dr Michael Baker as Chief Executive Officer and Managing Director, effective 5 October 2026, succeeding former CEO Dr James Garner. Baker brings a track record of transforming Arovell...
Percheron Therapeutics Issues 300 Million New Shares to Institutional and Sophisticated Investors
Percheron Therapeutics has issued 300,000,000 fully paid ordinary shares on 8 September 2026 following a placement to institutional and sophisticated investors, expanding its capital base and shareholder register. The company stated the shares were i...
Percheron Therapeutics to List 300 Million New Shares on ASX
Percheron Therapeutics Limited has applied for quotation of 300,000,000 new ordinary fully paid shares on the Australian Securities Exchange, with the securities scheduled to be issued on September 8, 2026. The move significantly increases the compan...
Percheron Therapeutics Sets Hybrid Annual General Meeting for October 2026
Percheron Therapeutics has issued a notice convening its annual general meeting for 10:00 a.m. AEDT on 7 October 2026, to be held at Hamilton Locke’s offices on Collins Street in Melbourne. The company will also provide a virtual attendance option vi...
Percheron updates investors as Vanderbilt trial advances HMBD-002
Percheron Therapeutics has released an updated non-confidential corporate presentation outlining its strategy in oncology and rare disease therapeutics. The materials highlight progress on HMBD-002, its next-generation immune checkpoint inhibitor, an...
Percheron Therapeutics Plans Issue of 50 Million Quoted Options
Percheron Therapeutics has lodged a notice with the ASX for a proposed issue of up to 50 million quoted options, each exercisable at A$0.01 and expiring on 15 April 2028, with an expected issue date of 15 October 2026. The planned options issuance, s...
Percheron Therapeutics Plans Major Share and Option Issuance on ASX
Percheron Therapeutics plans to issue up to 160 million new fully paid ordinary shares on the ASX as part of a placement or similar capital-raising initiative. The company will also issue up to 80 million free attaching quoted options, exercisable at...
Percheron Therapeutics Plans Major Share and Option Issue on ASX
Percheron Therapeutics has lodged a new Appendix 3B with the ASX detailing a proposed placement or other type of securities issue involving up to 300,000,000 ordinary fully paid shares. As part of the offer structure, the company plans to issue up to...
Percheron Therapeutics Details Equity Interests of New Director Deborah Ambrosini
Percheron Therapeutics Limited, an ASX-listed therapeutics company, has detailed the equity interests of newly appointed director Deborah Ambrosini. The disclosure highlights her holdings of fully paid ordinary shares and several tranches of unquoted...
Percheron Therapeutics Cancels Unmet Options in Director Incentive Plan
Percheron Therapeutics has disclosed a change in director James Garner’s interests, detailing adjustments to his holdings of unquoted options while his substantial shareholding of 74,900,000 fully paid ordinary shares remains unchanged. The notice ou...
Percheron Therapeutics Options Lapse Clarifies Future Dilution Profile
Percheron Therapeutics has notified the ASX of the cessation of two series of listed options after the conditions for their exercise were not met by the relevant deadline. A total of 2,672,500 options, with expiries in 2028 and 2029 at exercise price...
Percheron Seeks Trading Halt Ahead of Capital Raising Announcement
Percheron Therapeutics has requested and been granted a trading halt on its securities by the ASX, effective from 28 August 2026, as it prepares a market announcement. The halt will remain in place until either the company releases the pending news o...
Percheron taps Vanderbilt for AML trial of VISTA antibody HMBD-002
Percheron Therapeutics has entered a clinical research agreement with Vanderbilt Health in Nashville to conduct an investigator-sponsored trial of its VISTA-targeting antibody HMBD-002 in high-risk acute myeloid leukaemia and myelodysplastic syndrome...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 21, 2026